Today: 23 June 2026
Browse Category

Pharmaceuticals 29 December 2025 - 30 December 2025

AbbVie is acquiring Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal is expected to close in the third quarter and will bring AbbVie zumilokibart, an experimental long-acting drug for atopic dermatitis and other immune diseases. Apogee claims its top eczema drug could significantly reduce injection frequency compared to Dupixent, with Phase 3 trials planned for this year. Pfizer shares declined over the past week after CFO Dave Denton announced he will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession, execution, and competition from obesity-drug makers. Pfizer’s stock has also been affected by concerns over pricing pressure, patent cliffs, and a longer path to profitability in obesity drugs. Meanwhile, Novo Nordisk shares rose about 5% as healthcare stocks gained favor among investors seeking defensive positions, even as the company reported strong demand for its Wegovy pill. Alumis shares surged 15.55% ahead of Phase 2b lupus results due in the third quarter and a planned psoriasis NDA filing in the fourth quarter. Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected on July 29. Other notable moves include AtaiBeckley’s 7.8% rise following the start of its BPL-003 Phase 3 program and CervoMed’s premarket jump after a director-linked trust purchased $3 million in units, following a recent $10.5 million private placement.
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.
30 December 2025
··
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals shares dropped 4.2% to $107.85 in early afternoon trading Tuesday as biotech stocks broadly declined. Investors are awaiting an FDA decision on expanding Imcivree’s label, now expected by March 20, 2026. Board member Camille L. Bedrosian resigned effective immediately, according to an SEC filing. Major biotech ETFs fell over 1% while the broader market was flat.
30 December 2025
··
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics shares closed Monday up 8.8% at $1.98, then rose about 2% in after-hours trading ahead of the FDA’s Dec. 31 decision deadline for Lytenava in wet AMD. The stock remains volatile after an August FDA rejection sent shares down nearly 70%. Trading volume has surged, with the 20-day average at 3.35 million shares. Investors are watching for the FDA’s move, which could come outside regular market hours.
30 December 2025
·
BNAI stock doubles as Brand Engagement Network lands AI pharma deal, eyes recurring fees

BNAI stock doubles as Brand Engagement Network lands AI pharma deal, eyes recurring fees

Brand Engagement Network shares surged 108.8% to $2.51 Monday after announcing a pharma AI contract expected to bring $250,000 in Q4 revenue and monthly license fees in early 2026. Volume jumped to 148.6 million shares. The company reported $102,715 in cash at Sept. 30 and $60,120 in Q3 revenue. Traders are watching if BNAI holds above $2.50 after the spike.
30 December 2025
··
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk is cutting Wegovy prices in China, with local reports citing 48% reductions for the highest doses in Yunnan and Sichuan. The move comes as the company faces a 2026 patent expiry for semaglutide and rising competition from Chinese drugmakers. Novo shares fell after the China pricing news circulated. The company did not disclose exact new prices in its statement.
30 December 2025
·
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead Sciences shares closed up 0.15% at $124.91 on Monday after Bernstein said new Medicaid drug-pricing rules would have limited impact on its HIV drug Biktarvy. Bernstein estimated less than $200 million in 2026 revenue impact for older HIV drugs Genvoya and Odefsey. Investors await more details from the Trump administration’s pricing rollout and Gilead’s update at the J.P. Morgan Healthcare Conference in January.
30 December 2025
·
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, a cancer drug developer, on Monday. The company said it expects about $0.20 in adjusted EPS dilution, split between the fourth quarter and 2026. JNJ shares ended down 0.02% at $207.56. Investors await the Jan. 21 earnings call for 2026 guidance.
30 December 2025
····
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly shares rose 0.2% to $1,078.73 in after-hours trading Monday, with 1.64 million shares traded. Lilly Endowment Inc. disclosed the sale of 2,629 shares at $1,085.17 each, retaining over 92 million shares. Investors focused on obesity drug pricing, with Lilly and Novo Nordisk preparing pill versions and shifting to telehealth and direct-to-consumer sales. The S&P 500 fell 0.35% and the Nasdaq lost 0.5%.
29 December 2025
··
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb shares fell 0.7% to $54.27 in thin year-end trading Monday, underperforming the broader U.S. market. Investors are watching the Jan. 2 shareholder record date for its next dividend and the Feb. 5 earnings report. Peers were mixed, with Eli Lilly up and Pfizer down. Low volumes and year-end rebalancing drove volatility, according to traders.
29 December 2025
···
Merck stock holds steady as year-end trading thins and Wall Street slips

Merck stock holds steady as year-end trading thins and Wall Street slips

Merck shares slipped 0.1% to $106.68 midday Monday, outperforming broader U.S. markets as the S&P 500 ETF fell 0.6% and the Nasdaq-100 tracker dropped 0.7%. Trading volumes remained thin ahead of Federal Reserve minutes due Tuesday. Investors await Merck’s Feb. 3 earnings call for 2026 guidance and pipeline updates. Pending U.S. home sales rose 3.3% in November, beating forecasts.
29 December 2025
··
1 … 24 25 26 27 28 … 42

Stock Market Today

  • Ridgetech (RDGT) Stock Surges 68.6% in Nasdaq Premarket on Volume Spike
    June 23, 2026, 8:13 AM EDT. Ridgetech Inc. (Nasdaq: RDGT) shares jumped 68.6% to $2.31 in early premarket trading on June 23, 2026, with a surge in volume to 32.27 million shares. The healthcare distributor, valued at roughly $1.23 million market cap after a recent 1-for-150 reverse split, saw dramatic price swings due to thin trading and low float of fewer than 900,000 shares. The move occurred despite no new company announcements and amid a Nasdaq futures decline. HRT Financial LP, a 10% stakeholder, recently sold about 58,000 shares at $1.60 each. Market experts note the stock's susceptibility to volatility in extended hours and highlight the upcoming test at the regular Nasdaq opening when liquidity increases. Ridgetech operates in pharmaceutical wholesale, retail, and digital platforms in China.

Latest articles

Ridgetech (RDGT) Stock Jumps in Premarket as Volume Surges

Ridgetech (RDGT) Stock Jumps in Premarket as Volume Surges

23 June 2026
Ridgetech shares soared 68.6% to $2.31 in Nasdaq premarket trading on heavy volume, despite no new company news, after a major holder, HRT Financial LP, disclosed selling nearly 58,000 shares last week; with a tiny $1.23 million market cap and under 900,000 shares outstanding, the stock’s price is highly sensitive to trading swings ahead of the regular session open.
Korea Slides 10%, Nasdaq Futures Down 2.7% as Chip Stocks Sink Worldwide

Korea Slides 10%, Nasdaq Futures Down 2.7% as Chip Stocks Sink Worldwide

23 June 2026
Global semiconductor stocks plunged, wiping over $1 trillion from the Nasdaq 100’s market value in premarket trade as investors questioned whether massive AI infrastructure spending by tech giants can deliver returns, with SK Hynix and Samsung Electronics each losing over 12% and Micron set to report results that could further sway memory shares.
Micron Technology Stock Price Falls as $25 Billion Spending Plan Overshadows AI Forecast

Micron Earnings Take Center Stage for AI Stocks This Week

23 June 2026
Micron shares tumbled 8% premarket as investors brace for Wednesday’s earnings, with Wall Street raising the bar above company guidance after a record run; analysts warn that even a beat may disappoint if margins or outlook slip, threatening further stock and sector volatility amid soaring AI memory demand.
Go toTop